Monrust sodium improvement new drug appears! The first external gel preparation was applied for clinical use

Monrust sodium is a powerful selective white triene inhibitor antagonist (trade name: Singulair, Shunerning) developed by Merca Dongyuan, which specificly inhibits cysteine white triene in the airways, thus improving airway inflammation and effectively controlling asthma symptoms.
3 dosage forms, including tablets, chewing tablets, and particles.
the chewing tablets and granules are dosage forms developed specifically for pediatric asthma and allergic rhinitis patients.
According to the results of the pharmaceutical Rubik's Cube PharmaGo-China Declaration Library, domestic enterprises in addition to the development of the above three dosage forms of Mengluste sodium generic drugs, in the past has also tried to develop capsules, dispersion tablets, oral instant film and other oral preparation products, but no modified dosage form of products were approved for market.
Yujiang Yin Berryson Pharmaceutical Co., Ltd. this time submitted the Monrust sodium gel, not only belongs to the modified type of products, but also changed the way of dosing, and therefore belongs to the 2.2 category of improved new.
enterprises also submitted applications under class 2.4 new drugs (new adaptive drugs containing known active ingredients) indicating that the adaptive conditions to be developed by Monrust sodium gels are also different from previous respiratory diseases such as asthma and allergic rhinitis.
the Monrust sodium gel has any mystery? Perhaps from Jiangyin Beresen Pharmaceuticals applied for the preparation patent 201880002883.6 can be seen.
According to the patent statement, local preparations containing a combination of Monrust and mussel adhesive proteins can be used directly locally to treat inflammatory, inflammatory and/or inflammatory symptoms, including wounds, burns, psoriasis, acne and adiotic dermatitis.
mussel adhesion protein (MAP), also known as mussel psython protein, is a protein secreted by marine shellfish species, secreted by mussels from the foot silk gland, produced and stored in the foot silk gland.
All mussel adhesive proteins (including their subtypes) have two structural characteristics, (1) lysine, so that the protein carries a high positive charge charge (due to NH 2 end) ;(2) 3, 4-hydroxypropylaminate (DOPA, dopamine), its phthalates part is responsible for forming a strong co-priced bond.
, mussel adhesion proteins have a strong ability to bind to solid surfaces.
patent statement states that Monrust has never been given locally, for example, the skin to treat inflammation, and that existing technologies have not specifically publicly used a combination of products containing, in particular mussel adhesion proteins and Monrust, to treat, for example, inflammation.
example published in the patent by Jiangyin Beresen Pharmaceuticals shows that Monrust emulsions have potential efficacy in treating melanin calm and/or melanin-related skin diseases.
the study were patients with melanin-related skin diseases with symptoms including macular plaque and cheek rash.
subjects were asked to use emulsions after cleaning their faces in the morning and evening.
the subjects felt an improvement in skin color after 2 weeks of use.
As can be seen from the image below, the patient's skin symptoms gradually decreased 14 days before laser treatment (photo (a)), 7 days after the start of treatment with Monrust emulsion (photo (b)), and 14 days after treatment with Monrust emulsion (photo (c).
suggests that Monrust emulsions can be used to treat melanin calm and/or melanin-related skin diseases.
。